The Asia Pacific intranasal drug delivery devices market size surpassed USD 470 million in 2025 and is predicted to reach around USD 1433.89 million by 2035, registering a CAGR of 11.8% from 2026 to 2035. Due to rising respiratory diseases, increasing preference for non-invasive treatments, expanding healthcare infrastructure, growing awareness of nasal therapies and strong demand for faster drug absorption and self-administration options.

Asia Pacific Intranasal Drug Delivery Devices Market Statical Scope

The Asia Pacific inter nasal drug delivery devices market is witnessing rapid technological advancement, including the development of smart nasal sprays , dose control inhalers and needle-free delivery systems. Improved formulation techniques enhance drug stability and bioavailability. While precision engineered devices ensure accurate dosing, integration of digital health features and connective devices are also rising, enabling better patient monitoring and adherence. Additionally, innovation, spray mechanics and biocompatible materials are making treatment more efficient, compatible and patient friendly across diverse therapeutic areas.

Asia Pacific Intranasal Drug Delivery Devices Market, By System, 2025 (%)

• Metered Dose- The segment dominated the market with a 44.00% share, due to their precise dosing, improved patient compliance, and ability to deliver consistent drug safely and effectively.
• Multi-Dose Systems- The segment accounted for 35.00% of the total market share, due to their cost effectiveness, convenience, reduce packaging waste, and suitability for long term treatment add repeated patient use.
• Unit-Dose Systems- The segment accounted for 21.00% of the total market share, due to their high accuracy, single use convenience, improved hygiene, and reduce risk of contamination, making them ideal for emergency and paediatric applications.

Asia Pacific Intranasal Drug Delivery Devices Market, By Container, 2025 (%)

• Non-Pressurized Containers - The segment dominated the market with a 62.00% share, due to their low cost, simple design, ease of manufacturing, and widespread suitability for routine nasal drug administration.
• Pressurized Containers - The segment accounted for 38.00% of the total market share, due to their ability to deliver consistent sprays, better drug dispersion, improved absorption, add enhanced patient convenience for control dosing.

Asia Pacific Intranasal Drug Delivery Devices Market, By Application, 2025 (%)

• Chronic Obstructive Pulmonary Disease (COPD) - The segment accounted for 18.00% of the total market share, due to rising air pollution, ageing population is increasing demand for fast acting respiratory treatments.
• Rhinitis - The segment dominated the market with a 24.00% share, due to high allergy prevalence, seasonal triggers, pollution exposure and a strong preference for quick localised symptoms relief treatments.
• Cystic Fibrosis - The segment accounted for 9.00% of the total market share, due to its lower prevalence compared to other respiratory diseases, but still requires targeted nasal therapies for glucose clearance and infection management.

Asia Pacific Intranasal Drug Delivery Devices Market, By End User, 2025 (%)

• Ambulatory Surgical Centres- The segment accounted for 14.00% of the total market share, due to growing outpatient procedures, cost efficient care models, and increasing adoption of the intranasal devices for quick drug delivery.
• Clinics- The segment accounted for 26.00% of the total market share, due to increasing out-patient visits, easy accessibility, cost effective treatments, and growing use of therapies for quick symptoms relief.
• Hospitals- The segment dominated the market with a 50.00% share, due to advanced healthcare infrastructure, higher patient admissions, emergency care demand, and strong use of nasal therapies in acute treatments.

Top Companies in the Asia Pacific Intranasal Drug Delivery Devices Market

• Johnson & Johnson, Inc.
• Aptar Pharma Group
• GlaxoSmithKline Plc
• Aegis Therapeutics LLC
• H&T Presspart Manufacturing Ltd.
• AstraZeneca Plc
• Becton, Dickinson and Company
• Novartis AG
• Teleflex Incorporated
• Vectura Group Plc.

Segments Covered in the Report

By System

• Metered Dose
• Multi-Dose Systems
• Unit-Dose Systems

By Container

• Non-Pressurized Containers
• Pressurized Containers

By Application

• Rhinitis
• COPD (Chronic Obstructive Pulmonary Disease)
• Asthma
• Cystic Fibrosis
• Nasal Congestion
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centres
• Others